Aprea Therapeutics, Inc. Share Price
NASDAQ: APRE | Micro CapAprea Therapeutics, Inc. Stock Performance
Aprea Therapeutics, Inc. Share Price Chart
Aprea Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Aprea Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Aprea Therapeutics, Inc.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Aprea Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Oct 2026 | $0.69 | $0.51 | -34.62% |
Sep 2026 | $0.80 | $0.78 | -13.24% |
Aug 2026 | $0.59 | $0.90 | +38.10% |
Jul 2026 | $0.79 | $0.65 | -14.90% |
Jun 2026 | $0.83 | $0.77 | -17.30% |
May 2026 | $0.81 | $0.93 | +16.21% |
Apr 2026 | $0.71 | $0.80 | +0.89% |
Mar 2026 | $0.87 | $0.79 | -12.43% |
Feb 2026 | $0.73 | $0.90 | +15.51% |
Jan 2026 | $0.86 | $0.78 | -8.56% |
Dec 2025 | $1.23 | $0.85 | -32.83% |
Nov 2025 | $1.41 | $1.27 | -10.56% |